H Kanyerere1, B Girma2, J Mpunga1, K Tayler-Smith3, A D Harries4, A Jahn5, F M Chimbwandira6. 1. Community Health Science Unit, National Tuberculosis Control Programme, Lilongwe, Malawi. 2. Community Health Science Unit, National Tuberculosis Control Programme, Lilongwe, Malawi ; International Training and Education Center for Health (I-TECH) Malawi, Department of Global Health, University of Washington, Seattle, Washington, USA. 3. Medical Department, Médecins Sans Frontières, Operational Centre Brussels, Luxembourg City, Luxembourg. 4. International Union Against Tuberculosis and Lung Disease, Paris, France ; London School of Hygiene & Tropical Medicine, London, UK. 5. International Training and Education Center for Health (I-TECH) Malawi, Department of Global Health, University of Washington, Seattle, Washington, USA ; Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi. 6. Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi.
Abstract
Setting: For 30 years, Malawi has experienced a dual epidemic of human immunodeficiency virus (HIV) infection and tuberculosis (TB) that has recently begun to be attenuated by the scale-up of antiretroviral therapy (ART). Objective: To report on the correlation between ART scale-up and annual national TB case notification rates (CNR) in Malawi, stratified by HIV-positive and HIV-negative status, from 2005 to 2015. Design: A retrospective descriptive ecological study using aggregate data from national reports. Results: From 2005 to 2015, ART was scaled up in Malawi from 28 470 to 618 488 total patients, with population coverage increasing from 2.4% to 52.2%. During this time, annual TB notifications declined by 35%, from 26 344 to 17 104, and the TB CNR per 100 000 population declined by 49%, from 206 to 105. HIV testing uptake increased from 51% to 92%. In known HIV-positive TB patients, the CNR decreased from a high of 1247/100 000 to 710/100 000, a 43% decrease. In known HIV-negative TB patients, the CNR also decreased, from a high of 66/100 000 to 49/100 000, a 26% decrease. Conclusion: TB case notifications have continued to decline in association with ART scale-up, with the decline seen more in HIV-positive than HIV-negative TB. These findings have programmatic implications for national TB control efforts.
Setting: For 30 years, Malawi has experienced a dual epidemic of human immunodeficiency virus (HIV) infection and tuberculosis (TB) that has recently begun to be attenuated by the scale-up of antiretroviral therapy (ART). Objective: To report on the correlation between ART scale-up and annual national TB case notification rates (CNR) in Malawi, stratified by HIV-positive and HIV-negative status, from 2005 to 2015. Design: A retrospective descriptive ecological study using aggregate data from national reports. Results: From 2005 to 2015, ART was scaled up in Malawi from 28 470 to 618 488 total patients, with population coverage increasing from 2.4% to 52.2%. During this time, annual TB notifications declined by 35%, from 26 344 to 17 104, and the TB CNR per 100 000 population declined by 49%, from 206 to 105. HIV testing uptake increased from 51% to 92%. In known HIV-positive TB patients, the CNR decreased from a high of 1247/100 000 to 710/100 000, a 43% decrease. In known HIV-negative TB patients, the CNR also decreased, from a high of 66/100 000 to 49/100 000, a 26% decrease. Conclusion: TB case notifications have continued to decline in association with ART scale-up, with the decline seen more in HIV-positive than HIV-negative TB. These findings have programmatic implications for national TB control efforts.
Entities:
Keywords:
HIV/AIDS; Malawi; TB; antiretroviral therapy; human immunodeficiency virus
Authors: Rony Zachariah; Marie-Paule L Spielmann; Christina Chinji; Patrick Gomani; Victor Arendt; Nicola J Hargreaves; Felix M Salaniponi; Anthony D Harries Journal: AIDS Date: 2003-05-02 Impact factor: 4.177
Authors: R Zachariah; M Bemelmans; A Akesson; P Gomani; K Phiri; B Isake; T van den Akker; M Philips; A Mwale; F Gausi; J Kwanjana; A D Harries Journal: Int J Tuberc Lung Dis Date: 2011-07 Impact factor: 2.373
Authors: Jens D Lundgren; Abdel G Babiker; Fred Gordin; Sean Emery; Birgit Grund; Shweta Sharma; Anchalee Avihingsanon; David A Cooper; Gerd Fätkenheuer; Josep M Llibre; Jean-Michel Molina; Paula Munderi; Mauro Schechter; Robin Wood; Karin L Klingman; Simon Collins; H Clifford Lane; Andrew N Phillips; James D Neaton Journal: N Engl J Med Date: 2015-07-20 Impact factor: 91.245
Authors: S E Collins; M A Jean Juste; S P Koenig; R Secours; O Ocheretina; D Bernard; C Riviere; M Calnan; A Dunning; S M Hurtado Rúa; W D Johnson; J W Pape; D W Fitzgerald; P Severe Journal: Int J Tuberc Lung Dis Date: 2015-01 Impact factor: 2.373
Authors: Amitabh B Suthar; Stephen D Lawn; Julia del Amo; Haileyesus Getahun; Christopher Dye; Delphine Sculier; Timothy R Sterling; Richard E Chaisson; Brian G Williams; Anthony D Harries; Reuben M Granich Journal: PLoS Med Date: 2012-07-24 Impact factor: 11.069
Authors: Henry Kanyerere; Anthony D Harries; Katie Tayler-Smith; Andreas Jahn; Rony Zachariah; Frank M Chimbwandira; James Mpunga Journal: Trop Med Int Health Date: 2015-11-16 Impact factor: 2.622
Authors: K Rees; N Muditambi; M Maswanganyi; J Railton; J A McIntyre; H E Struthers; P B Fourie; R P H Peters Journal: Epidemiol Infect Date: 2017-12-06 Impact factor: 4.434
Authors: Andrew Tomita; Catherine M Smith; Richard J Lessells; Alexander Pym; Alison D Grant; Tulio de Oliveira; Frank Tanser Journal: Sci Rep Date: 2019-07-24 Impact factor: 4.379
Authors: Scott A Nabity; Laurence J Gunde; Diya Surie; Ray W Shiraishi; Hannah L Kirking; Alice Maida; Andrew F Auld; Michael Odo; Andreas Jahn; Rose K Nyirenda; John E Oeltmann Journal: PLoS One Date: 2021-04-01 Impact factor: 3.240
Authors: Anthony D Harries; Yan Lin; Ajay M V Kumar; Srinath Satyanarayana; Kudakwashe C Takarinda; Riitta A Dlodlo; Rony Zachariah; Piero Olliaro Journal: F1000Res Date: 2018-07-05
Authors: Diya Surie; Martien W Borgdorff; Kevin P Cain; Eleanor S Click; Kevin M DeCock; Courtney M Yuen Journal: BMC Infect Dis Date: 2018-09-26 Impact factor: 3.090